Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents
Table 2
The kinetics of the immunological parameters during the treatment of patients with chronic hepatitis C and their comparison with healthy controls.
Parameter
CHC patients
Healthy controls
value
0 w
4 w
12 w
0 W–HC
4 W–0 W
12 W–0 W
4 W–12 W
12 W–HC
CD14++CD16− monocyte cells (%)
59.14 ± 0.54
67.59 ± 1.98
71.54 ± 2.99
72.75 ± 1.31
ns
ns
ns
CD14+CD16+ monocyte cells (%)
18.49 ± 1.54
13.39 ± 1.07
12.42 ± 1.60
ns
ns
CD3−CD16+CD56+NK cells (%)
13.29 ± 0.85
12.68 ± 1.09
14.44 ± 1.60
18.72 ± 1.91
ns
ns
ns
ns
Serum sCD14 (pg/mL)
64407.38 ± 5778.49
51639.83 ± 5778.49
44390.06 ± 3330.17
28370.76 ± 2357.68
ns
ns
Serum sCD163 (pg/mL)
22853.80 ± 4137.61
11975.35 ± 1795.91
11494.79 ± 1836.97
2934.41 ± 223.31
ns
Serum IL-12 (pg/mL)
2.98 ± 0.13
2.61 ± 0.13
2.51 ± 0.10
2.49 ± 0.1
ns
ns
ns
Serum IL-18 (pg/mL)
76.51 ± 11.01
52.73 ± 5.00
40.63 ± 3.72
11.45 ± 1.77
ns
ns
Serum CXCL-10 (pg/mL)
64.41 ± 6.16
37.64 ± 5.22
29.09 ± 3.49
10.48 ± 0.43
ns
Serum CXCL-11 (pg/mL)
23.64 ± 3.54
15.53 ± 2.07
9.64 ± 1.77
8.27 ± 2.19
ns
ns
ns
CHC patients: chronic hepatitis C patients; ; ; ; ns: no significance.
